跳转至内容
Merck
CN

EHU080901

Sigma-Aldrich

MISSION® esiRNA

targeting human DLX4

登录查看公司和协议定价

关于此项目

UNSPSC代码:
41105324
NACRES:
NA.51
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

描述

Powered by Eupheria Biotech

质量水平

产品线

MISSION®

表单

lyophilized powder

esiRNA cDNA靶序列

GGAGAAAAAGGAATGGAGCAGAGCCTGTACCCCTAACCCTAACAGCTAAATCAAGGACCTCAGCCTTATATAATCATTGTCCCCACCACTACCATGGACTGGACACCTTCACTCCAGCTGGACAAAGACTCTGGAGAGAGAGCCATTGGCTGGAGTTGAGACTGTCCCCAGAACCCTTGGTCTTGCCACTCCCCCACTCCTTCTTCCCTCTCTCCCTTTCTCCTCTCCCTGCTTTCTTGAAAAGGACTGAATCGCCACTACAGCCTGGGTGCAAAATCAGCAAGAAACATTGAGTATTTTTTTTTCTTTGTATGCCTTTGGCCTTGCACAACCCATTTGTGAGCAAAAGCAGAAGTGGACCACCATCAGCTCCCACCCACCCAGCGATTTTTCCTTGGAGGTCA

基因组数据库 |人类登记号

NCBI登记号

运输

ambient

储存温度

−20°C

基因信息

一般描述

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法律信息

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

10 - Combustible liquids

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Yinxiang Lv et al.
Anti-cancer drugs, 28(8), 861-868 (2017-06-20)
Calcein acetoxymethyl ester (calcein-AM) treatment has been reported to exert antitumor effects in certain cancer cells; however, the detailed mechanism of action of calcein-AM in cancers remains unclear, especially in nonsmall cell lung cancer (NSCLC). This study focused on the
Yinxiang Lv et al.
Drug design, development and therapy, 10, 3053-3064 (2016-10-13)
Resistance to chemotherapeutic drugs is a major obstacle in non-small cell lung cancer (NSCLC) therapy. The molecular determinants of NSCLC resistance to doxorubicin are unknown. In the present study, we investigated whether topoisomerase IIβ binding protein 1 (TopBP1) was involved
Balabhadrapatruni V S K Chakravarthi et al.
Molecular cancer research : MCR, 16(7), 1125-1137 (2017-10-14)
In aggressive prostate cancers, the oncoprotein STMN1 (also known as stathmin 1 and oncoprotein 18) is often overexpressed. STMN1 is involved in various cellular processes, including cell proliferation, motility, and tumor metastasis. Here, it was found that the expression of
Shiyuan Hong et al.
Oncogene, 38(17), 3274-3287 (2019-01-12)
High-risk human papillomaviruses (HPVs) constitutively activate ataxia telangiectasia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) DNA damage repair pathways for viral genome amplification. HPVs activate these pathways through the immune regulator STAT-5. For the ATR pathway, STAT-5 increases expression
Rune Troelsgaard Pedersen et al.
The Journal of cell biology, 210(4), 565-582 (2015-08-19)
Genome integrity is critically dependent on timely DNA replication and accurate chromosome segregation. Replication stress delays replication into G2/M, which in turn impairs proper chromosome segregation and inflicts DNA damage on the daughter cells. Here we show that TopBP1 forms

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持